Patients with prostate cancer treated by ADT have significantly higher fibrinogenemia than healthy control
World Journal of Urology, 08/20/2012
Ziaran S et al. – This is the first study that demonstrates the significant increase in fibrinogen in prostate cancer (PCa) patients on androgen deprivation therapy, while C–reactive protein as inflammatory marker did not increase. Elevation of serum level of fibrinogen may contribute to increased cardiovascular risk in PCa patients.